Greenleaf Trust Sells 445 Shares of Novo Nordisk A/S (NYSE:NVO)

Greenleaf Trust cut its holdings in Novo Nordisk A/S (NYSE:NVO) by 0.7% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 65,909 shares of the company’s stock after selling 445 shares during the period. Greenleaf Trust’s holdings in Novo Nordisk A/S were worth $6,818,000 at the end of the most recent quarter.

Other institutional investors also recently modified their holdings of the company. Pacific Center for Financial Services boosted its stake in Novo Nordisk A/S by 100.0% in the third quarter. Pacific Center for Financial Services now owns 270 shares of the company’s stock valued at $25,000 after acquiring an additional 135 shares during the last quarter. Copeland Capital Management LLC lifted its stake in Novo Nordisk A/S by 100.0% in the third quarter. Copeland Capital Management LLC now owns 282 shares of the company’s stock valued at $26,000 after purchasing an additional 141 shares during the last quarter. Bell Investment Advisors Inc grew its holdings in Novo Nordisk A/S by 79.9% during the third quarter. Bell Investment Advisors Inc now owns 286 shares of the company’s stock valued at $26,000 after purchasing an additional 127 shares during the period. Citizens National Bank Trust Department increased its position in Novo Nordisk A/S by 100.0% in the third quarter. Citizens National Bank Trust Department now owns 300 shares of the company’s stock worth $27,000 after buying an additional 150 shares during the last quarter. Finally, Tyler Stone Wealth Management raised its stake in shares of Novo Nordisk A/S by 100.0% in the third quarter. Tyler Stone Wealth Management now owns 292 shares of the company’s stock valued at $27,000 after buying an additional 146 shares during the period. 11.54% of the stock is owned by institutional investors.

Novo Nordisk A/S Price Performance

Shares of NVO stock traded down $0.05 during trading hours on Friday, reaching $122.70. The stock had a trading volume of 5,181,119 shares, compared to its average volume of 4,882,816. The stock’s fifty day simple moving average is $126.36 and its 200 day simple moving average is $110.50. The firm has a market capitalization of $550.62 billion, a PE ratio of 45.55, a PEG ratio of 2.08 and a beta of 0.41. Novo Nordisk A/S has a 12 month low of $75.56 and a 12 month high of $138.28. The company has a current ratio of 0.82, a quick ratio of 0.64 and a debt-to-equity ratio of 0.19.

Novo Nordisk A/S (NYSE:NVO) last released its quarterly earnings results on Wednesday, January 31st. The company reported $0.71 earnings per share for the quarter, topping the consensus estimate of $0.66 by $0.05. The firm had revenue of $9.51 billion for the quarter, compared to analysts’ expectations of $9.14 billion. Novo Nordisk A/S had a net margin of 36.03% and a return on equity of 90.36%. On average, equities research analysts predict that Novo Nordisk A/S will post 3.32 EPS for the current year.

Novo Nordisk A/S Increases Dividend

The firm also recently declared a Semi-Annual dividend, which was paid on Tuesday, April 2nd. Stockholders of record on Monday, March 25th were given a dividend of $0.664 per share. This represents a dividend yield of 0.9%. The ex-dividend date of this dividend was Friday, March 22nd. This is an increase from Novo Nordisk A/S’s previous Semi-Annual dividend of $0.22. Novo Nordisk A/S’s dividend payout ratio (DPR) is 49.17%.

Analysts Set New Price Targets

Several research analysts have recently weighed in on the company. BMO Capital Markets began coverage on Novo Nordisk A/S in a research note on Friday, April 12th. They set an “outperform” rating and a $163.00 price target for the company. Morgan Stanley initiated coverage on shares of Novo Nordisk A/S in a research note on Tuesday, January 23rd. They issued an “overweight” rating and a $120.00 target price for the company. Cantor Fitzgerald reissued an “overweight” rating and issued a $160.00 price target on shares of Novo Nordisk A/S in a research report on Thursday. Finally, UBS Group started coverage on shares of Novo Nordisk A/S in a report on Tuesday, January 16th. They issued a “neutral” rating for the company. Two investment analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $133.60.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.